SGMO earnings analysis
What we found in SGMO's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Sangamo Therapeutics reported a significant decline in revenues for Q1 2026, generating only $1.44 million, a decrease of 77.6% year-over-year, and an EPS of -$0.11, missing expectations. The company faces critical liquidity challenges, with cash expected to last only until Q3 2026, and continues to explore various strategic options, including potential bankruptcy.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Massive Revenue Decline
- Total revenue decreased by $4.99 million to $1.44 million, down 77.6% from $6.437 million YOY.
- Consistent EPS Loss
- EPS reported at -$0.11, down from -$0.08 in the previous year.
- Operating Expenses Decrease
- Total operating expenses declined by $2.7 million to $33.4 million, down 7% from the year prior.
- Increased Cash Reserves
- Cash and cash equivalents rose to $27.6 million from $20.9 million at year-end.
- Sustained R&D Expenditure
- R&D expenses rose slightly by $0.6 million to $26.6 million, mainly due to BLA readiness activities.
- Active Stock Sale Program
- $129.5 million remains available under the sales agreement as of March 31, 2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Potential Bankruptcy
- Management warns of a possible need to cease operations or liquidate assets if additional funding is not secured.
- Delisted from Nasdaq
- The company's stock was suspended from Nasdaq trading on May 5, 2026, following ongoing compliance failures.
- Severe Cash Flow Concerns
- With current cash reserves, liquidity is expected to last only until Q3 2026, posing a significant operational risk.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.11
What they said about what is next.
Management anticipates substantial operational cuts unless significant capital is raised.
The filing reads worse than the one before it.
What came before.
- 10-K · April 29, 2026
- Sangamo Therapeutics, Inc. reported troubling financial results for the year ended December 31, 2025, with significant declines in revenue and large operating losses. The company's performance indicates potential for…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing SGMO makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever